期刊文献+

甲状腺乳头状癌组织与癌旁组织中长链非编码RNA表达谱分析 被引量:10

Study on expression profile of long non-coding RNA in thyroid papillary carcinoma
原文传递
导出
摘要 目的 建立甲状腺乳头状癌组织与癌旁组织中长链非编码RNA (lncRNA)差异表达谱.方法 分别提取5例甲状腺乳头状癌患者癌组织和癌旁组织中的RNA,体外逆转录制备并标记双链DNA,用含有39000条lncRNA的双通道基因芯片检测,对原始数据进行归一化处理及差异分析.结果 芯片筛选出差异表达的lncRNA 26 924条.有明显差异的lncRNA共245条(变化>2倍,P <0.05),这其中在肿瘤组织中高表达的IncRNA 73条,低表达的lncRNA 172条.变化在3倍以上的lncRNA共40条,差异在4倍以上的lncRNA有2条.结论 甲状腺乳头状癌组织与癌旁组织比较,其lncRNA表达谱发生明显改变,提示lncRNA可能参与甲状腺乳头状癌的发生. Objective To analysis the expression profile variation of long non-cording RNA (lncRNA) in thyroid papillary carcinoma and normal thyroid tissue.Methods Total RNA from the thyroid papillary carcinoma tissue and normal thyroid tissue of 5 patients with thyroid papillary were prepared respectively.Hybridization was performed with the profile chip containing 39 000 human lncRNAs.After the scanning of Agilent scanner,data were normalized and analyzed by using the Agilent GeneSpring software.Results Compared with normal thyroid tissue,26 923 lncRNAs expressed differentially,245 lncRNAs were significantly differential (fold change 〉 2 ; P 〈 0.5) in thyroid papillary carcinoma tissue,in which 73 lncRNAs were up-regulation and 172 lncRNAs were down-regulation.Conclusion Obvious changes of lncRNA expression profile were observed in the pathogenesis of thyroid papillary carcinoma,lncRNA may be related to the progress of thyroid papillary carcinoma.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2014年第11期2548-2550,共3页 Chinese Journal of Experimental Surgery
基金 国家自然科学基金资助项目(81270449) 山东省自然科学基金资助项目(ZR2012HM046)
关键词 甲状腺乳头状癌 长链非编码RNA 芯片 Thyroid papillary carcinoma Long non-cording RNA Microarray
  • 相关文献

参考文献5

二级参考文献31

  • 1Ponting CP,Oliver PL,Reik W.Evolution and functions of long noncoding RNAs.Cell,2009,136:629-641.
  • 2Struhl K.Transcriptional noise and the fidelity of initiation by RNA polymerase Ⅱ.Nat Struct Mol Biol,2007,14:103-105.
  • 3Huarte M,Guttman M,Feldser D,et al.A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response.Cell,2010,142:409-419.
  • 4Lotan Y,Svatek RS,Sagalowsky AI.Should we screen for bladder cancer in a high risk population? A cost per life-year saved analysis.Cancer,2006,107:982-990.
  • 5van Rhijn BW,van der Poel HG,van der Kwast TH. Urine markers for bladder cancer surveillance:a systematic review.Eur Urol,2005,47:736-748.
  • 6Budman LI,Kassouf W,Steinberg JR.Biomarkers for detection and surveillance of bladder cancer.Can Urol Assoc J,2008,2:212-221.
  • 7Wang XS,Zhang Z,Wang HC,et al.Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma.Clin Cancer Res,2006,12:4851-4858.
  • 8Ding R,Li B,Muthukumar T,et al.CD103 mRNA levels in urinary cells predict acute rejection of renal allografts.Transplantation,2003,75:1307-1312.
  • 9Chan RW,Tam LS,Li EK,et al.Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis.Arthritis Rheum,2003,48:1326-1331.
  • 10de Kok JB,Verhaegh GW,Roelofs RW,et al.DD3 (PCA3),a very sensitive and specific marker to detect prostate tumors.Cancer Res,2002,62:2695-2698.

共引文献55

同被引文献74

引证文献10

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部